People with proliferative diabetic retinopathy may develop another eye condition called macular edema. The macula is the part of the retina that processes the images in the center of your vision ...
In this video, Jay Chhablani, MD, director of clinical research at the UPMC Vision Institute, professor of ophthalmology and vice chair of clinical trials at University of Pittsburgh School of ...
Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA ® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer ...
When AMD first develops, you may not notice any symptoms. Over time, though, it may cause blurry vision and/or change the appearance of colors. Some people may also develop dark areas in the center of ...
If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are indicated ...
The US Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals’ supplemental biologics licence application (sBLA) for Eylea HD (aflibercept) injection 8mg for priority review. The ...
TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...
Eylea and Eylea HD are prescription medications used to treat various eye conditions. The dosage and frequency of injections of these drugs vary based on the specific condition and the form of the ...
Regeneron Pharmaceuticals (NASDAQ:REGN) announced that the U.S. FDA has extended the target action dates for two regulatory submissions related to Eylea HD (aflibercept) injection 8 mg to the fourth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results